- Home
- LXEH vs ONCO Comparison
LXEH vs ONCO Comparison
Compare LXEH & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LXEH | ONCO |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 3.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | LXEH | ONCO |
|---|---|---|
| Price | $1.70 | $0.66 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.1K | ★ 382.5K |
| Earning Date | 05-01-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.80 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $815,371.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.16 | $0.09 |
| 52 Week High | $3.28 | $6.73 |
Technical Indicators
Market Signals| Indicator | LXEH | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 43.48 |
| Support Level | $1.55 | $0.61 |
| Resistance Level | $2.30 | $1.01 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 60.62 | 16.10 |
Price Performance
Historical ComparisonAbout LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is engaged in providing education services, including high school and vocational education services. It offers private basic education at the primary and junior high school levels. The Group has two reportable segments for operations, including high school and vocational education.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.